- Home
- MRM vs CANF Comparison
MRM vs CANF Comparison
Compare MRM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- CANF
- Stock Information
- Founded
- MRM 2000
- CANF 1994
- Country
- MRM Japan
- CANF Israel
- Employees
- MRM N/A
- CANF N/A
- Industry
- MRM Other Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- CANF Health Care
- Exchange
- MRM Nasdaq
- CANF Nasdaq
- Market Cap
- MRM 10.4M
- CANF 9.6M
- IPO Year
- MRM 2020
- CANF N/A
- Fundamental
- Price
- MRM $1.64
- CANF $0.65
- Analyst Decision
- MRM
- CANF Strong Buy
- Analyst Count
- MRM 0
- CANF 2
- Target Price
- MRM N/A
- CANF $14.50
- AVG Volume (30 Days)
- MRM 7.6M
- CANF 140.0K
- Earning Date
- MRM 05-20-2025
- CANF 08-26-2025
- Dividend Yield
- MRM N/A
- CANF N/A
- EPS Growth
- MRM 27.65
- CANF N/A
- EPS
- MRM 0.18
- CANF N/A
- Revenue
- MRM $52,786,758.00
- CANF $560,000.00
- Revenue This Year
- MRM N/A
- CANF $461.72
- Revenue Next Year
- MRM N/A
- CANF N/A
- P/E Ratio
- MRM $9.04
- CANF N/A
- Revenue Growth
- MRM 21.55
- CANF N/A
- 52 Week Low
- MRM $0.34
- CANF $0.63
- 52 Week High
- MRM $5.30
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- MRM 47.41
- CANF 36.29
- Support Level
- MRM $1.42
- CANF $0.63
- Resistance Level
- MRM $1.97
- CANF $0.68
- Average True Range (ATR)
- MRM 0.20
- CANF 0.02
- MACD
- MRM -0.06
- CANF 0.01
- Stochastic Oscillator
- MRM 27.85
- CANF 42.80
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).